Stockwinners Market Radar for December 30, 2021 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:34 EST Cathie Wood's ARK Investment bought 194.7K shares of Block today

20:33 EST Cathie Wood's ARK Investment bought 543.2K shares of DraftKings today

20:31 EST Quipt Home Medical announces receipt of management cease trade order - Quipt Home Medical "announces that, further to its December 16, 2021 news release, its application for a management cease trade order under National Policy 12-203 - Management Cease Trade Orders has been approved by the British Columbia Securities Commission. The MCTO does not affect the ability of investors to trade in the securities of the company."

18:23 EST Four Corners Property Trust buys Chick-fil-A Property for $3.5M - Four Corners Property Trust announces the acquisition of a Chick-fil-A property for $3.5M. The property is located in retail corridor in Connecticut and is corporate-operated with approximately fifteen years of term remaining. The transaction was priced at a cap rate in range with previous FCPT transactions.

18:04 EST Four Corners Property Trust acquires Caliber Collision property for $3.0M - Four Corners Property acquired a Caliber Collision property for $3.0M. The property is located in a dense corridor in Pennsylvania and is corporate-operated with approximately eight years of term remaining. The transaction was priced at a 6.2% going-in cash capitalization rate, exclusive of transaction costs.

17:19 EST CTO Realty Growth acquires Phase I of The Exchange at Gwinnett for $34M - CTO Realty Growth announced it has acquired Phase I of The Exchange at Gwinnett, a grocery-anchored retail property in the Buford submarket of Atlanta, Georgia for $34M. The purchase price represents a going-in cap rate within the range of the company's guidance for initial cash yields. The company also announced the sale of a vacant six-acre development land parcel in downtown Daytona Beach, Florida for $6.3M. The company purchased the property using available cash and availability under the company's unsecured revolving credit facility.

17:01 EST American Electric completes sale of Racine hydroelectric plant - American Electric completed the sale of Racine Plant, a 48 MW hydroelectric facility in Racine, Ohio, from AEP Generation Resources, the company's competitive generation affiliate, to Eagle Creek Renewable Energy. The sale price will not be disclosed. With the completion of this transaction, AEP Generation Resources' only remaining competitive facility is Cardinal Plant's 595-MW Unit 1, which is scheduled for retirement in 2028.

16:55 EST Titan Medical discloses Nasdaq non-compliance notice - Titan Medical received notification from the Nasdaq Stock Market LLC Listing Qualifications Department that it was not in compliance with the minimum bid price requirement set forth in Nasdaq Rule 5550(a)(2) since the closing bid price for the company's common shares listed on Nasdaq was below US$1.00 for 30 consecutive business days. These notifications do not impact the company's listing on the Nasdaq Capital Market at this time. In accordance with Listing Rule 5810(c)(3)(A), the company has a period of 180 calendar days from the date of notification, being until June 28, 2022, to regain compliance with the minimum bid price requirement, during which time the shares will continue to trade on the Nasdaq Capital Market.

16:35 EST Xeris Biopharma's Recorlev approved by FDA for Cushing's syndrome - Xeris Biopharma announced the FDA approval of Recorlev for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome for whom surgery is not an option or has not been curative. The approval of Recorlev was based upon safety and efficacy data from two positive Phase 3 studies that evaluated a population of 166 patients representative of the adult drug-treated U.S. population with Cushing's syndrome. The study met its primary and key secondary endpoints, significantly reducing and normalizing mean urinary free cortisol concentrations without a dose increase A randomized-withdrawal study that met its primary and key secondary endpoints, confirmed the efficacy and safety of Recorlev in normalizing and maintaining therapeutic response compared with placebo. Endogenous Cushing's syndrome is a rare, serious, and potentially fatal endocrine disease caused by chronic elevated cortisol exposure-often the result of a benign tumor of the pituitary gland. The disease is most common among adults between the ages of 30-50, and it affects women three times more often than men.

16:19 EST Archaea Energy launches Project Assai RNG facility - Archaea Energy announced the successful start-up of Project Assai, an RNG facility located at the Keystone Sanitary Landfill in Dunmore, Pennsylvania. Pipeline-quality RNG has been produced and commercial operations were achieved on December 30. Assai is now the highest capacity operational RNG facility in the world. Assai was successfully constructed, commissioned, and completed within budget and in under two years. Assai has an inlet capacity of 22,500 scfm and combines landfill gas flows from the Keystone Sanitary Landfill and the Waste Management Alliance Landfill. Assai is expected to reduce CO2 emissions by over 200,000 metric tons annually and reduce air pollutants. Assai is expected to deliver over 4 million MMBtu of RNG annually at projected flows, methane recovery and uptime, resulting in over $40M of annual projected EBITDA. Approximately 80% of the total RNG volumes expected to be produced at Assai have been contracted on a long-term, fixed fee basis with FortisBC Energy Inc., Energir, L.P., and The Regents of the University of California, for periods of up to 20 years.

16:16 EST AMD, Xilinx now see transaction closing in first quarter of 2022 - AMD (AMD) and Xilinx (XLNX) released the following statement related to the status of global regulatory approvals for AMD's proposed acquisition of Xilinx: "We continue making good progress on the required regulatory approvals to close our transaction. While we had previously expected that we would secure all approvals by the end of 2021, we have not yet completed the process and we now expect the transaction to close in the first quarter of 2022. Our conversations with regulators continue to progress productively, and we expect to secure all required approvals." There are no additional changes to the previously announced terms or plans regarding the transaction and the companies continue to look forward to the proposed combination "creating the industry's high-performance and adaptive computing leader," the companies stated.

16:15 EST Colfax to hold special shareholder meeting to seek approval of reverse split - Colfax announced that it plans to hold a special meeting of stockholders to seek approval for an amendment to the company's Amended and Restated Certificate of Incorporation to effect, at the discretion of the Board of Directors, (i) a reverse stock split of the company's common stock, par value $0.001 per share at one of three reverse stock split ratios, one-for-two, one-for-three or one-for-four, with the exact ratio to be determined by the Board of Directors of the company at a later date, and (ii) if and when the reverse stock split is effected, a corresponding reduction in the number of authorized shares of our common stock by the selected reverse stock split ratio.

16:12 EST Lexicon submits NDA for Sotagliflozin in type 2 diabetes related heart failure - Lexicon "announced that it has submitted a New Drug Application to the U.S. Food and Drug Administration seeking approval for the marketing and sale of sotagliflozin to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent visits for heart failure in adult patients with type 2 diabetes with either worsening heart failure or additional risk factors for heart failure irrespective of left ventricular ejection fraction. The FDA has a 60-day filing review period to determine whether the NDA is complete and acceptable for filing. The NDA submission is supported by the results from the Phase 3 SOLOIST clinical study in patients with type 2 diabetes who had recently been hospitalized for worsening heart failure and the Phase 3 SCORED clinical study in patients with type 2 diabetes, chronic kidney disease and risks for cardiovascular disease."

16:10 EST Sonoco Products acquires American Recycling - Sonoco Recycling, a unit of Sonoco, "announced it has acquired American Recycling of Western North Carolina, a privately owned recovered paper recycler located in Asheville, N.C. American Recycling of Western North Carolina is a privately owned business that processes approximately 30,000 tons of recovered fiber annually at its well-capitalized Asheville material recovery facility. The business expects to generate approximately $9 million in sales in 2021 and it is strategically located approximately 65 miles from Sonoco's Newport, TN, uncoated recycled paperboard mill."

16:08 EST Centene, Magellan Health obtain all required regulatory approvals for deal - Centene (CNC) and Magellan Health (MGLN) announced that they have obtained all required regulatory approvals necessary to close Centene's pending acquisition of Magellan Health. Subject to the satisfaction of customary closing deliveries, the parties anticipate closing the acquisition on or about January 4, 2022.

16:00 EST Xeris Pharmaceuticals trading halted, news pending

15:32 EST SCWorx announces settlements of securities class action, derivative action suits - SCWorx announced that it has entered into binding agreements to settle both the securities class action and derivative action lawsuits which were commenced in 2020. Under the terms of the class action agreement, the insurers for the company and former CEO Marc Schessel will make a cash payment to the class plaintiffs and the company will issue $600,000 worth of common stock to the class plaintiffs, in exchange for which all parties will be released from all claims related to the securities class action litigation. The class action agreement provides that the parties will negotiate in good faith to enter into a definitive settlement agreement within thirty days. Once the company issues the $600,000 worth of stock, the company believes it will have satisfied its obligations with respect to the payment of the $750,000 accrued retention liability applicable to its D&O insurance policy. The final settlement agreement will be subject to court approval. "One of my primary goals since becoming CEO of SCWorx has been to resolve the class and derivative actions and move forward with focusing on our core data management business. I would like to thank our Board, management team and legal counsel in helping to achieve these goals and put these issues behind us. We look forward to continuing to deliver our SaaS service offerings to healthcare providers as they struggle with the difficulties caused by Covid-19. Our service offerings help solve the challenges which hospitals experience within their supply chain and deliver the analytics and visibility to achieve desired cost savings," said Tim Hannibal, CEO of SCWorx.

14:13 EST Avista announces long-term clean energy contract with Chelan PUD - Avista and Chelan County Public Utility District, or PUD, have finalized a contract for renewable hydropower from the PUD's two hydro projects on the Columbia River, the company announced. "The 20-year contract increases Avista's carbon-free resources toward its 2030 renewable energy goals, as well as contributes flexible capacity to identified needs in Washington and Idaho. The acquisition successfully closes out Avista's 2020 Renewable Request for Proposals. The competitively priced contract provides Avista with 5% of the output from the PUD's Rock Island and Rocky Reach hydropower projects from 2026 through 2030; it increases to 10% of the output from these projects in 2031-2045... The contract was negotiated after a competitively bid RFP process and includes both carbon-free energy attributes provided by hydropower as well as dispatchable capacity to help Avista meet peak energy needs during high customer usage times," the company stated.

13:30 EST Teva 'strongly disagrees' with New York jury ruling in opioids trial - The company said, "Teva Pharmaceuticals strongly disagrees with today's outcome and will prepare for a swift appeal as well as continue to pursue a mistrial. In NY, the plaintiffs presented no evidence of medically unnecessary prescriptions, suspicious or diverted orders, no evidence of oversupply by the defendants - or any indication of what volumes were appropriate - and no causal relationship between Teva's conduct including its marketing and any harm to the public in the state. Prior to deliberation, Teva sought a mistrial based on, among other issues, the state's misrepresentation of the amount of opioids sold by Teva in NY by more than 500 times. Teva continues to focus on increasing access to essential medicines to patients, including opioid medications for approved indications. Most importantly, the Company continues to pursue a national settlement in the best interest of patients. As recently as last month, a court in California issued a decision finding that Teva did not cause a public nuisance in Orange County, Los Angeles County, Santa Clara County and the City of Oakland and that Teva did not make any false or misleading statements in connection with marketing prescription opioids in California. Additionally, last month the Oklahoma Supreme Court overturned an earlier judgment against a pharmaceutical manufacturer and ruled that the public nuisance law in Oklahoma does not extend to the manufacturing, marketing and selling of prescription opioids."

12:21 EST Cruise stocks lower after CDC says even vaccinated should avoid ships

12:11 EST Teva down 4% after NY jury said to find company liable in opioid suit - Shares of Teva trading in New York are down about 4% to $8.09 in midday trading after Bloomberg's Jef Feeley reported that a jury in New York concluded that the company and some of its units should be held liable for helping to fuel a public-health crisis via the marketing and distribution of opioid painkillers. Feeley, who noted that the company could face "potentially billions in compensation claims" from New York state and two Long Island counties, noted that the judge in the case will decide later how much the state and counties should get related to the jury verdict.

12:00 EST Kuke Music falls -6.1% - Kuke Music is down -6.1%, or -28c to $4.42.

12:00 EST Vector Group falls -36.0% - Vector Group is down -36.0%, or -$6.17 to $10.99.

12:00 EST Tencent Music rises 14.2% - Tencent Music is up 14.2%, or 84c to $6.81.

11:42 EST FireBird Energy announces acquisition of Midland Basin assets from Chevron - FireBird Energy announced that it has completed an acquisition of operated assets located in the Midland Basin from Chevron U.S.A. Inc. and Chevron Midcontinent, L.P. The acquisition closed December 30, with an effective date of December 1, FireBird said. Travis Thompson, CEO of FireBird, said, "This transaction will be our second major acquisition as we continue to advance our consolidation strategy and enhance our Western Midland Basin footprint with additional scale. The acquisition of these high-margin, oil-weighted assets is a complementary addition to our acreage footprint, production, and cash flow base. The Acquisition includes approximately 21,000 net acres, 99% operated, in Ector, Midland, Crane, and Upton Counties. We expect to benefit from additional operating synergies when production operations are combined with our base asset."

10:02 EST Ocugen partner Bharat Biotech announces COVAXIN immunogenicity, safety data - Ocugen announced that its partner, Bharat Biotech, posted results from a Phase 2/3 trial conducted in India of candidate vaccine, COVAXIN, in children, aged 2 - 18 years, demonstrating a robust neutralizing antibody response and favorable safety profile on the pre-print server, medRXiv. Using a two-dose regimen administered 28-days apart, antibody responses in subjects were comparable to adult data from a previous phase 3 study. Those results demonstrated a greater than 93% reduction in severe disease. These pediatric data were the basis of Ocugen's pediatric Emergency Use Authorization submission in the United States for children 2-18 on November 5, 2021. In the study, immunogenicity against key COVID-19 proteins was measured using geometric mean titer, a test that measures the amount of antibodies in the blood in response to the presence of the virus. GMT was measured across three age groups and demonstrated strong immune response after the second dose. There were no serious adverse events such as myocarditis, pericarditis, or blood clots, reported in any of the three age groups. This immunobridging trial was intended to determine if COVAXIN generates the same protective immunity in children as it does in adults. To be considered equivalent, pediatric participants needed to achieve comparable GMT's to those generated by adults in a large phase 3 clinical trial. At Day 56, across all ages, the mean SARS-CoV-2 antibody GMT was more than 30% higher in children aged 2-18 than the mean GMT from Phase 3 clinical trial involving 25,800 adult subjects aged 18+. These data demonstrate children 2-18 generate antibody response comparable to adults fully vaccinated with COVAXIN. The study also showed increased antibody titers against 3 viral antigens providing a broad immune response to COVID-19. In each case a more than 4-fold increase in neutralizing antibody titers versus baseline was seen in all age groups after the second dose. Participants were not reported to have experienced any severe adverse events. The majority of adverse events noted were mild and a small proportion were moderate . Mild to moderate adverse events resolved within 24 hours. The data were also submitted to the Drugs Controller General of India to support a pediatric indication as recommended by an independent committee, known as the Subject Expert Committee, that advises the Indian regulatory agency. Bharat Biotech intends to submit data from the full Phase 3 trial to a peer-reviewed scientific publication soon.

10:00 EST Turkcell falls -4.3% - Turkcell is down -4.3%, or -17c to $3.67.

10:00 EST Sonida Senior Living rises 7.4% - Sonida Senior Living is up 7.4%, or $2.08 to $30.34.

10:00 EST Tencent Music rises 8.4% - Tencent Music is up 8.4%, or 50c to $6.47.

09:47 EST Korea Electric Power falls -3.8% - Korea Electric Power is down -3.8%, or -37c to $9.28.

09:47 EST R.R. Donnelley rises 4.8% - R.R. Donnelley is up 4.8%, or 51c to $11.18.

09:47 EST Studio City rises 6.8% - Studio City is up 6.8%, or 40c to $6.24.

09:39 EST SuperCom chairman purchases 512,000 shares in open market - SuperCom announced that its Chairman of the Board, Mr. Arie Trabelsi, has notified the Company that he has purchased recently 512,000 SPCB shares in the open market, as part of his purchase program to purchase up to 3 million SPCB shares in the Open Market.

09:17 EST Royal Caribbean provides update on COVID-19, omicron variant impact - Royal Caribbean Group provided an update on the status of its business and the impact of the Omicron variant. "Knowledge about COVID-19 and how to deal with it have been in a constant state of flux for the last two years. Omicron has significantly altered the COVID-19 landscape for everyone, and the Royal Caribbean Group is no exception," the company said. "Omicron is having a big short-term impact on everyone, but many observers see this as a major step towards COVID-19 becoming endemic rather than epidemic," said Richard Fain, Chairman & CEO. "We don't like to see even one case, but our experience is a fraction of the comparable statistics of virtually any other comparable location or industry. Few businesses are subject to such intense scrutiny, regulation, and disclosure requirements by so many authorities, and we welcome that scrutiny because of our commitment to safety. We intend to maintain our goal of delivering the safest vacation on land or sea and will constantly adjust our procedures to accomplish this even in the face of Omicron's amazing transmissibility." The company experienced a decline in bookings and increased cancellations for near-term sailings but to a lesser degree than that experienced with the Delta variant. Load factors for sailings in the first half of 2022 remain below historical levels, as expected. However, sailings for the second half of 2022 continue to be booked within historical ranges, at higher prices with and without Future Cruise Credits, with strong demand from the critical U.S. market. The travel industry is experiencing significant disruptions by air transport and other service providers due to the spread of omicron. Such disruptions are particularly impactful during the holiday season as the need increases and the labor supply is impacted by the current spike in cases. Similar issues are impacting the company's onboard service capabilities. In addition, the company is experiencing service disruptions at selected destinations and to date has cancelled or significantly modified 16 destination calls out of 331. The company expects these disruptions to continue in the near term and then decline as the world adjusts to the current trends. Fain concluded, "We are constantly learning and adjusting as Omicron appears to be ushering in a new phase in the fight against COVID-19. We expect these factors to have a negative impact in the short term but are optimistic they will lead us to a more pervasive but less severe health environment. Taken together, this should enable us to produce a strong transitional year in 2022 and a very strong 2023."

09:14 EST Royal Caribbean says first half of 2022 load factors below historical levels

09:03 EST EnWave signs second equipment purchase agreement for 120kW REV machine - EnWave Corporation announces that it has signed a second equipment purchase agreement to sell a second 120kW Radiant Energy Vacuum dehydration machine to a leading Illinois-based cannabis company that has operations in multiple U.S. States. The MSO signed a royalty-bearing commercial license agreement with EnWave and purchased its first 120kW REV machine in March 2021.

08:59 EST Sypris Solutions wins award for Army Key Management System - Sypris Electronics, LLC, a subsidiary of Sypris Solutions, "announced that it has recently received a follow-on award from a U.S. DOD prime contractor to manufacture and test embedded circuit card assemblies that will perform certain cryptographic functions for the Army Key Management System, or AKMS. Production is expected to begin in 2022. Terms of the agreement were not disclosed."

08:53 EST Biofrontera AG announces reduction of Biofrontera Inc. shareholding to under 50% - Biofrontera announced that through the exercise of outstanding warrants the majority ownership of Biofrontera AG (BFRA) was diluted below 50%. Biofrontera AG's shareholding in Biofrontera Inc. (BFRI) of 8,000,000 shares is unchanged, but now represents approximately 47% of the currently outstanding shares. As a result, Biofrontera Inc. is no longer considered a subsidiary of Biofrontera AG. Biofrontera Inc.'s common stock and warrants are traded on the Nasdaq Capital Market under the ticker symbols "BFRI" and "BFRIW," respectively. Not affected by this will be Biofrontera AG's position as Licensor for the license and supply agreement with Biofrontera Inc, which provides the latter with the exclusive rights to market and sell Ameluz and the PDT-lamps BF-RhodoLED and RhodoLED XL in the United States.

08:48 EST Enbridge completes sale of financial interest in Noverco - Enbridge announced the closing of the agreement through which a subsidiary of Enbridge has sold its 38.9% non-operating minority ownership interest in Noverco to Trencap for $1.14B in cash, previously announced on June 7, 2021. "The sale of our financial interest in Noverco Inc. will further strengthen our financial flexibility. Proceeds from the sale will be initially used to repay short term borrowings and support Enbridge's secured capital program," the company said.

08:44 EST Tesla recalls all 2017-2020 Model 3 vehicles - According to a letter "serving to acknowledge Tesla, Inc.'s notification to the National Highway Traffic Safety Administration of a safety recall," the EV maker is "recalling all 2017-2020 Model 3 vehicles. The rearview camera cable harness may be damaged by the opening and closing of the trunk lid, preventing the rearview camera image from displaying... Tesla Service will inspect and install a guide protector and new cable harness as necessary, free of charge."Reference Link

08:39 EST Rise Education announces closing of sale of three subsidaries - RISE Education Cayman announced that it has closed its previously announced sale, in which, the company has sold all of the equity interests in Rise Education Information Consulting to Wuhan Xinsili Culture Development on December 28, 2021; and all of the equity interests in RISE Education International Limited and Rise IP to Bain Capital Rise Education IV Cayman Limited on December 30, 2021. Upon completion of the Sale, the Company has, through its subsidiaries, sold substantially all of its assets. In connection with the Sale, on December 30, 2021, the settlement with the lenders of the facilities agreement dated March 18, 2021 relating to the term and revolving facilities of up to an aggregate amount of $80M has also been completed. As part of the Settlement, all interest in the Edge business that offers admission consulting, academic tutoring and test preparation services in Hong Kong and Singapore for students who intend to study abroad has been transferred to a person nominated by the Lenders.

08:35 EST Blue Owl Capital completes acquisition of Oak Street Real Estate Capital - Blue Owl Capital announced the completion of its acquisition of Oak Street Real Estate Capital and its investment advisory business. The transaction was previously announced in October of 2021. Doug Ostrover, Co-Founder and CEO of Blue Owl, said: "We are thrilled to officially welcome Marc and the Oak Street team to Blue Owl. Oak Street is the industry's preeminent net lease platform with meaningful capital, scale and expertise that will further expand Blue Owl's range of investment solutions. We look forward to working closely together and are excited for what the future holds."

08:32 EST American Shared Hospital appoints Kathleen Miles, Vicki Wilson to board - American Shared Hospital Services announced changes to its Board of Directors. The changes will result in five total Board members, one less than currently. The Board has elected two new directors, Kathleen Miles and Vicki Wilson, effective December 28, 2021. Sandra Lawrence resigned from the Board, effective December 24, 2021. Ernest Bates, M.D. and David Larson, M.D. resigned from the Board, effective December 28, 2021. Dr. Bates and Dr. Larson will both become consultants to the Company. Kathleen Miles currently serves as Chief Counsel, Public Finance, of The PNC Financial Services Group. Vicki Wilson currently serves as Deputy Director, Finance and Administration and Chief Fiscal Officer of the State of Illinois Department of Public Health.

08:12 EST CECO delivered aluminum chip, recycling solution to aluminum manufacturer - CECO Environmental announced that its CECO Busch brand recently delivered an integrated, multi-product line, aluminum chip collection and recycling solution to a leading provider of aluminum plates, sheeting and extrusions in North America for its new milling system. This system is currently under construction and will be fully operational in early 2022. The integrated solution is designed to collect tons of aluminum scrap that is a standard byproduct of aluminum mill producers. "CECO is pleased to provide aluminum manufacturers with advanced solutions to help our customers recover high volumes of aluminum scrap for recycling," said Todd Gleason, CEO, CECO Environmental. "Our solutions deliver an efficient way to recycle excess aluminum that is discarded during the manufacturing process thereby significantly reducing waste, which reduces a manufacturer's impact on the environment and assists with meeting sustainability initiatives. Aluminum manufacturing continues to be critically important to a range of industries including food and beverage packaging, automotive, aerospace and construction."

08:11 EST Osisko Mining announces TSX approval to renew normal course issuer bid - Osisko Mining announces that the Toronto Stock Exchange has approved the Corporation's notice of intention to make a normal course issuer bid. Under the terms of the NCIB Program, Osisko may acquire up to 28,678,891 of its common shares from time to time in accordance with the normal course issuer bid procedures of the TSX. The normal course issuer bid will be conducted through the facilities of the TSX or alternative trading systems, if eligible, and will conform to their regulations. Purchases under the normal course issuer bid will be made by means of open market transactions or such other means as a securities regulatory authority may permit, including pre-arranged crosses, exempt offers and private agreements under an issuer bid exemption order issued by a securities regulatory authority. Repurchases under the NCIB Program may commence on January 2, 2022 and will terminate on January 1, 2023 or on such earlier date as the NCIB Program is complete. Daily purchases will be limited to 138,745 Common Shares, other than block purchase exemptions, representing 25% of the average daily trading volume of the Common Shares on the TSX for the six-month period ending November 30, 2021, being 554,981 Common Shares. The price that the Corporation may pay for any Common Shares purchased in the open market under the NCIB Program will be the prevailing market price at the time of purchase and any Common Shares purchased by the Corporation will be cancelled. In the event that the Corporation purchases Common Shares by pre-arranged crosses, exempt offers, block purchases or private agreements, the purchase price of the Common Shares may be, and will be in the case of purchases by private agreements, as may be permitted by the securities regulatory authority, at a discount to the market price of the Common Shares at the time of acquisition. The board of directors of Osisko believes that the underlying value of the Corporation may not be reflected in the market price of the Common Shares from time to time and that, accordingly, the purchase of Common Shares will increase the proportionate interest in the Corporation of, and be advantageous to, all remaining shareholders of the Corporation. As of December 20, 2021, there were 346,279,008 Common Shares issued and outstanding. The 28,678,891 Common Shares that may be repurchased under the NCIB Program represent approximately 10% of the public float of the Corporation as of December 20, 2021, being 286,788,917 Common Shares. During the prior NCIB Program of the Corporation, which will end on January 1, 2022, the Corporation obtained approval to purchase 28,304,260 Common Shares, and actually purchased 12,892,600 Common Shares at a weighted average price of approximately $3.2076 per Common Share through the facilities of the TSX.

08:10 EST Vector Group announces completion of Douglas Elliman spin-off - Vector Group has completed the spin-off of Douglas Elliman into a standalone, publicly traded company. Douglas Elliman's common stock will begin "regular way" trading on the New York Stock Exchange on December 30, under the symbol "DOUG" and Vector Group will continue to trade on the NYSE under the symbol "VGR". Vector Group will continue to operate its tobacco business, which includes the manufacturing and sale of cigarettes in the U.S. through its subsidiaries Liggett Group LLC and Vector Tobacco Inc., and will continue to own interests in numerous properties and real estate projects across the U.S. through New Valley . "Vector Group is well positioned to continue driving revenue growth and margin improvement by strengthening our tobacco brand portfolio and continuing to improve operating efficiency," said Howard M. Lorber, Chairman and Chief Executive Officer of Vector Group. "This spin-off enables Vector Group to continue capitalizing on the attractive value proposition in the deep discount segment of the tobacco market and enhances our strategic flexibility as a standalone company."

08:09 EST BeyondSpring expects cash to support ongoing programs over the next year - As of September 30, 2021, the Company had cash, cash equivalents, and short-term investments of $91.6M. The Company believes it has sufficient cash to support its ongoing clinical programs over the next year, including its immuno-oncology pipeline.

08:09 EST MicroStrategy bought 1,914 bitcoins for $94.2M in last three weeks - In a regulatory 8-K filing, MicroStrategy states: "On December 30, 2021, MicroStrategy announced that, during the period between December 9, 2021 and December 29, 2021, the company purchased approximately 1,914 bitcoins for approximately $94.2M in cash, at an average price of approximately $49,229 per bitcoin, inclusive of fees and expenses. As of December 29, 2021, the company held approximately 124,391 bitcoins that were acquired at an aggregate purchase price of $3.75B and an average purchase price of approximately $30,159 per bitcoin, inclusive of fees and expenses."

08:06 EST Future FinTech announces new blockchain division - Future FinTech announced that the company has established a new blockchain division that will manage its existing blockchain sector business which will include the further formulation and execution of its strategic growth plan. Zhi Yan has been appointed as the president of the new division to direct the Company's blockchain business. At present, the blockchain division's primary mission will be to develop, operate and manage the Company's previously announced bitcoin mining farm plans in the United States and Paraguay, and to coordinate its announced Dubai-based digital currency trading service and crypto asset management business via its FTFT Capital Investments LLC subsidiary. Kai Xu has been appointed as the vice president of the new division.

08:04 EST Kroger board of directors approves $1B share repurchase authorization - The Kroger Co.'s board of directors today authorized a new $1B share repurchase program, replacing the current authorization, which had approximately $157M remaining as of December 29, 2021. "We are customer obsessed and focused on leading with fresh and accelerating with digital, which is building momentum in our business and will drive Kroger's long-term success," said Rodney McMullen, Kroger's chairman and CEO. "Kroger's share repurchase authorization reflects our Board of Directors' confidence in the strength of our free cash flow and our ability to deliver consistently strong and attractive total shareholder returns."

08:02 EST Ascend receives final NY State approval for investment agreement with Medmen - Ascend Wellness (AAWH) announced it has received final approval from the New York Cannabis Control Board, CCB, and the Office of Cannabis Management of the CCB for its previously announced definitive investment agreement with MedMen NY, the New York subsidiary of MedMen Enterprises (MMNFF). AWH has given notice to MedMen of its intent to close the transactions contemplated by the Investment Agreement imminently.

07:50 EST Draganfly selected to implement health, safety program during CES 2022 - Draganfly is pleased to announce that the Company's Varigard pathogen and surface sanitizer spray will be implemented ahead of the Drone Racing League's Vegas Championship Race Presented by T-Mobile outside T-Mobile Arena and the EDGE22 plenary sessions at the Park Theater in the Park MGM in Las Vegas, Nevada. Both events are taking place during the Consumer Electronics Show, which is running from January 5-8, 2022. Draganfly's Varigard pathogen and surface spray will be administered in partnership with Global Aerial Management Group.

07:34 EST Exro Technologies partners with United Motorcycles - Exro Technologies announced that it has initiated a partnership with Untitled Motorcycles to "demonstrate the advantages of Exro's patented Coil Driver technology in Untitled Motorcycles' award-winning XP Zero electric motorcycle," the company said. In entering this partnership, the two companies will collaborate to integrate Exro's 100 Volt Coil Driver technology into XP Zero electric motorcycles. Exro will provide technology and integration support, while using Untitled Motorcycles' design and development knowledge.

07:32 EST Revival Gold provides summary on 2021 highlights at Beartrack-Arnett - Revival Gold is pleased to provide a summary of the Company's key 2021 accomplishments advancing the past-producing Beartrack-Arnett Gold Project located in Idaho, USA. Highlights: Drilling in five core holes for 2,400 meters continued to show promise on the main five-kilometer Beartrack-Arnett trend including the high-grade underground Joss target, which returned 4.34 g/t gold over 110.6 meters, one of the best intercepts ever reported on the project. 2021 results further defined high-grade mineralization which extends for more than one kilometer of strike at Joss and remains open on strike and at depth. All eighteen holes that have intersected the target structure at Joss to date have cut broad intervals of lower-grade mineralization ranging from 2 - 4 g/t gold containing narrower, higher-grade intervals with grades ranging from 4 - 11 g/t gold over estimated true widths of 1 - 5 meters. In the Haidee area, initial results from 2021 drilling in 15 core holes for 2,500 meters continued to upgrade and extend this near-surface oxide gold target. Final results are expected in January. A resource update for the Beartrack-Arnett project area is targeted for completion in the first quarter of 2022. Meanwhile, Revival Gold continued de-risking the project by advancing metallurgical test work on 2.7 tonnes of material where bottle roll test results at three crush sizes were consistent with, or more favourable than, recovery assumptions used in the Company's 2020 Preliminary Economic Assessment. Column tests were also initiated to investigate heap leach characteristics to potentially improve recovery and economics. Geotechnical and hydrological work was initiated to provide open pit and leach pad design criteria in support of mineral resource estimation and a planned heap leach Pre-Feasibility Study. Studies have been undertaken to optimize capital, mine life and production planning. The Company also commenced baseline environmental data collection and planning to facilitate a potential return to production. Continued to show the potential benefits of the Beartrack-Arnett gold project to local communities in Lemhi County, Idaho through an independently authored study into economic impacts. Findings included $1.2 billion in cumulative contribution to Idaho State Gross Domestic Product over an eight-year period, the creation of an average 858 full-time direct and indirect jobs and $87 million and $121 million of cumulative contribution to State of Idaho and Federal tax revenues. Achieved an exemplary safety record with zero lost-time incidents among Company employees and contractors. Built on the Company's financial and technical credentials with the appointment of Lisa Ross as VP & CFO and, most recently, John Meyer as VP Engineering & Development. Both individuals bring leadership depth and relevant recent development and operating experience to Revival Gold. Commenced trading on OTCQX market in the USA, giving the Company exposure to a broader pool of investors.

07:18 EST Cemex to sell Costa Rica and El Salvador operations for $335M - Cemex "announced that it has signed an agreement for the sale of its operations in Costa Rica and El Salvador with Cementos Progreso Holdings, S.L., through its subsidiaries, for a total consideration of approximately $335M. This transaction further advances the goal under CEMEX's strategic plan, Operation Resilience, to optimize its global portfolio. The divested assets consist of 1 fully integrated cement plant, 1 grinding station, 7 ready-mix plants, 1 aggregate quarry and 1 distribution center in Costa Rica, and 1 distribution center in El Salvador."

07:14 EST Red White & Bloom Brands settles C$5.1M debt, refinances C$12.8M note - Red White & Bloom Brands has issued 6,784,812 shares to settle a C$5.1M debt. The weighted average conversion price is approximately C$0.75 per share. By settling the debt at a favorable conversion price, RWB will realize an accounting gain of approximately C$2.3M. Further to its press release of April 28, 2021, RWB has refinanced the C$12.8M principal amount of its "Seven month" vendor take-back note issued to High Street Capital Partners, LLC, in connection with RWB Florida LLC's acquisition of all of the issued and outstanding shares of Acreage Florida. To refinance, RWB entered into an agreement for an aggregate principal amount of approximately C$14.6M secured debenture on November 29, 2021 from an arm's length investor. The Debenture bears interest at the rate of 10% per annum and matures on May 30, 2022 unless accelerated under certain circumstances. Additionally, on December 21, 2021, RWB granted the following: 500,000 stock options to a member of the board of directors at the price of C$0.40. The shares will vest in one year. 135,000 restricted share units to a subcontractor for services at a deemed price of C$1.00. The RSUs vest on issuance. All securities issued are subject to a four month and one day hold period from issuance in accordance with applicable securities laws.

07:05 EST ProQR Therapeutics announces amendment to convertible debt financing agreement - ProQR Therapeutics announced that it has amended its convertible debt financing agreement entered into in 2020 with Kreos Capital and Pontifax Medison Debt Financing. The amended agreement provides ProQR with access to up to an additional $90M in convertible debt financing in three new tranches of $30M each that will mature over a 54 month period and have an interest-only period of 33 months. The three new tranches replace the two undrawn tranches under the original convertible debt financing agreement. Pontifax and Kreos may elect to convert the new tranches into ProQR ordinary shares at any time prior to repayment at a conversion price of $11.94 per share, which is a 50% premium to the Company's average closing share pricing during the 7 trading days prior to signing. ProQR also has the ability to convert the loan into its ordinary shares, at the same conversion price, if the Company's stock reaches a pre-determined threshold. In connection with the amendment and drawdown of the first new tranche, ProQR has agreed to issue at closing of the amendment warrants to purchase up to an aggregate of 83,767 and 293,185 to entities affiliated with Pontifax and Kreos, respectively, of its ordinary shares at an exercise price of $11.94 per share, which is a 50% premium to the average closing price during the 7 trading days prior to signing. In addition, at the time of drawing of each of the new second and third tranches, ProQR shall issue to Pontifax and Kreos additional warrants to purchase an aggregate number of ordinary shares with an aggregate exercise price of $750,000, with each such issuance of additional warrants being exercisable for a number of ordinary shares equal to $750,000 divided by 1.5 times the average closing price of ProQR's ordinary shares during the 7 trading days prior to the drawing of the relevant tranche.

07:03 EST Green Thumb Industries closes acquisition of LeafLine Industries - Green Thumb Industries announced it has closed on an acquisition of LeafLine Industries. As one of only two licensed cultivators in the Minnesota medical cannabis market, LeafLine is licensed to grow, process and dispense cannabis directly to patients. The acquisition of LeafLine includes a cultivation facility and five open and operating retail locations in Eagan, Hibbing, St. Cloud, St. Paul and Willmar. Green Thumb will also maintain the opportunity to open up to three additional retail locations in the state. With the acquisition, Green Thumb has cannabis operations to serve over 50% of the United States population, including in: California, Colorado, Connecticut, Florida, Illinois, Maryland, Massachusetts, Minnesota, Nevada, New Jersey, New York, Ohio, Pennsylvania, Rhode Island and Virginia. With a population of nearly six million people, Minnesota began medical cannabis sales in 2015 and currently has only about 29,000 registered active patients according to the Minnesota Department of Health. The state currently has 17 qualifying conditions, including chronic pain, multiple sclerosis, post-traumatic stress disorder and seizures. Products available include vape, tinctures and topicals, with flower and edibles coming later in 2022. Green Thumb's presence in Minnesota will further enhance and support the medical cannabis patient community through its high-quality branded products and experiences.

06:47 EST Helen of Troy completes acquisition of Osprey Packs - Helen of Troy Limited announced the completion of its previously announced acquisition of Osprey Packs, Inc, for $414.7M in cash, which includes the impact of a $5.3M favorable customary closing net working capital adjustment. Founded in 1974, Osprey is a longtime U.S. leader in technical and everyday packs. Its outstanding product lineup includes a wide range of backpacks and daypacks for hiking, mountaineering, skiing, climbing, mountain biking, trail running, commuting, and school, as well as a rugged adventure travel packs, wheeled luggage, and travel accessories.

06:10 EST Mindset Pharma provides recap 2021 milestones, highlights - Mindset Pharma provided a recap of its 2021 milestones and highlights. "In 2021, we made significant progress in building our portfolio of next-generation psychedelic compounds showing improved preclinical safety and efficacy of 5-MeO-DMT and psilocybin-based therapies," said James Lanthier, CEO of Mindset. "As we enter 2022, we are excited to advance these novel therapies towards the clinic as we progress IND-enabling studies for our lead candidate, MSP-1014, and select additional candidates from our other families of compounds. 2021 was, however, just the beginning for Mindset; we are building the industry's leading drug discovery platform and intend to continue to break new ground in psychedelic drug discovery in order to bring patented, safe and effective therapies to those suffering from a range of mental illnesses and neurological disorders." Operational Highlights: Expanded Patent Portfolio: Filed four provisional patent applications bringing the total to eight provisional applications filed to-date. Mindset also has filed four final PCT applications, which cover a broad range of novel, next generation drugs inspired by psilocybin, DMT, & 5-MeO-DMT and a novel psilocybin synthesis and manufacturing method. Advanced First Lead Drug Candidate Toward Clinical Trials: Selected its first lead clinical candidate, MSP-1014, a differentiated psilocybin-based analog, to move forward into investigational new drug-enabling studies. Growing Library of Novel Compounds: Synthesized over 100 novel compounds in more than 500 in vitro and in vivo studies. Developed First-in-Class Benchmarking: Under the Cooperative Psychedelics Evaluation Platform program, Mindset and its partner, InterVivo Solutions, continued to develop first-in-class benchmarking data across first-generation psychedelic drugs. Effect Size & Safety Differentiation Driven by Technology Platform: Preclinical data generated across the four families of novel chemical entities resulted in the identification of a platform technology that enhances effect size and improves safety profiles of psychedelic drugs. A provisional patent application was filed in May of 2021. Enhanced Leadership and Advisory Teams: Appointed Dr. Malik Slassi as Senior Vice President of Innovation, Mr. Ian Dean as Director of Preclinical Development, and Drs. Michael Rogawski, Guy Higgins, Joseph Gabriele and Ishrat Husain to its Scientific Advisory Board.

06:07 EST Parex Resources announces approval of NCIB, automatic share purchase plan - Parex Resources announced that the Toronto Stock Exchange has approved the Company commencing a normal course issuer bid. Pursuant to the Bid, Parex will purchase for cancellation, from time to time, as it considers advisable, up to a maximum of 11,820,533 common shares of the Company. The Bid will commence on January 4, 2022 and will terminate on January 3, 2023 or such earlier time as the Bid is completed or terminated at the option of Parex. The maximum number of common shares to be purchased pursuant to the Bid represents 10% of the public float, as of December 22, 2021. Purchases pursuant to the Bid will be made on the open market through the facilities of the TSX and/or alternative trading systems. The number of common shares that can be purchased pursuant to the Bid is subject to a daily maximum of 119,661 common shares. The price that Parex will pay for any common shares under the Bid will be the prevailing market price on the TSX at the time of such purchase. Common shares acquired under the Bid will be cancelled. Parex believes that the common shares have been trading in a price range which does not adequately reflect their value in relation to the Company's current operations and its growth prospects, and that, at such times, the purchase of common shares for cancellation will increase the proportionate interest of, and be advantageous to, all remaining shareholders. As of the close of business on December 22, 2021, the Company had 120,555,447 common shares issued and outstanding and a public float of 118,205,330. Under a previous notice of intention to conduct a normal course issuer bid, the Company sought and received approval of the TSX to purchase 12,868,562 Common Shares for the period from December 23, 2020 to December 22, 2021. From December 23, 2020 to December 22, 2021, the Company has purchased 12,868,562 Common Shares on the open market at a weighted average price of $21.25 per Common Share. Further, the Company has entered into an automatic share purchase plan with Peters & Co. Limited in order to facilitate repurchases of its common shares. Under the Company's automatic share purchase plan, Peters & Co. Limited may repurchase shares under the normal course issuer bid during the Company's self-imposed blackout periods. Purchases will be made by Peters & Co. Limited based upon the parameters prescribed by the TSX and applicable securities laws and the terms of the plan and the parties' written agreement. The automatic share purchase plan has been approved by the Toronto Stock Exchange and will be implemented effective January 4, 2022.

06:04 EST Inogen appoints Elizabeth Mora as board chairperson - Inogen announced that Elizabeth Mora was elected as Board Chairperson. Ms. Mora has served as a member of Inogen's Board of Directors since May 24, 2021, and is also a member of the Audit and Compliance Committees. She assumes the role from Heath Lukatch, Ph.D., who has served as Chairperson of the Board since 2008. Dr. Lukatch will remain on the Board as a director and member of the Compensation Committee. In addition, Ray Huggenberger, who has served on the Board since 2008, is retiring from the Board, and transitioning to an advisory role. Ms. Mora will replace Mr. Huggenberger as Chair of the Compliance Committee. Following Mr. Huggenberger's retirement, the Board has been reduced to seven members. In connection with these Board changes, Inogen director Kristen Miranda, has reclassified and become a Class III director, joining with Dr. Lukatch. Class I directors are comprised of Heather Rider and Ms. Mora and Class II directors are comprised of Loren McFarland, Benjamin Anderson-Ray and Nabil Shabshab.

05:57 EST Codex DNA, Pfizer enter license agreement with $8M upfront payment - Codex DNA disclosed yesterday morning that it entered into a research collaboration and license agreement with Pfizer (PFE), pursuant to which the company and Pfizer agreed to collaborate to develop improvements to the company's existing proprietary BioXP platform including associated instruments, kits/reagents, workflows and other methods. Under the Agreement, during a limited term, Codex DNA and Pfizer will conduct the R&D Program "with the goals of developing the Improved Platform and generating specified Pfizer Outputs." The company granted Pfizer a non-exclusive, worldwide license to use the Improved Platform for purposes of researching, developing, manufacturing and commercializing pharmaceutical and biopharmaceutical products and a limited-time option to convert such license to exclusive for specific applications. Under the agreement, Pfizer will make an upfront payment to Codex DNA of $8M and if the company meets certain technical milestones, it will be eligible to receive an additional $10M in near-term milestone payments. In addition, Pfizer has agreed to make milestone payments to the company upon the products meeting certain clinical milestones, with each product being eligible for milestone payments up to $35M if it were to meet the applicable clinical milestones and the first exclusive product in each exclusive field being eligible for milestone payments up to $55M if it were to meet the applicable clinical milestones. Pfizer has also agreed to pay the company up to $60M in sales milestones for products f aggregate net sales of such products meet certain thresholds and up to $180M in sales milestones for exclusive products if aggregate net sales meet certain thresholds. Provided the agreement remains in place, Pfizer will also pay escalating royalties from low to mid-fraction of one percent of net sales of products.

05:09 EST FSD Pharma announces share repurchase program - FSD Pharma announced that its board has authorized the repurchase by the company of up to 2M of its Subordinate Class B Voting Shares from time to time over the next 12 months at prevailing market prices in order to allow the company to use its excess cash reserves. The company will purchase up to 2M subordinate voting shares, being approximately 5% of the company's issued and outstanding Subordinate Voting Shares as of the date hereof. The share repurchase program will commence on January 4, 2022 and terminate on December 30, 2022, unless terminated earlier by the company. The share repurchase program does not obligate the company to purchase any subordinate voting shares. If management decides it has a better use for its cash reserves, it is under no obligation to continue to purchase Subordinate Voting Shares and share purchases may be suspended or terminated at any time at the company's discretion.